Plain-English translation of NCT05660811 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is for people with kidney disease on dialysis who have recently had a procedure to close a small pouch in the heart (using an Amplatzer or WATCHMAN device) to help prevent stroke. The study is testing which schedule of blood-thinning medications—like aspirin and clopidogrel—works best after this procedure, and how long patients should take them to stay safe while avoiding bleeding problems.
People with kidney disease and heart rhythm problems face a tricky situation: they need protection against stroke but are also at higher risk for dangerous bleeding. The current guidance on the best blood-thinning approach after this heart procedure doesn't have enough information about these kidney patients, so this study aims to fill that gap.
You likely qualify if…
You likely don't qualify if…
After your heart procedure, you will be randomly assigned to take blood-thinning medications on one of four different schedules—some people will take two medications for 30 days then one for the long term, others for 6 months then one for the long term, and so on. You'll visit the study center for check-ups and imaging tests to make sure the device is working well and that the medication plan is safe for you. The study tracks you over several months to compare which approach has the fewest blood clots and bleeding problems.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Poland